XM은(는) 미국 국적의 시민에게 서비스를 제공하지 않습니다.
T
T

ThermoFisher


뉴스

U.S. Constellation Energy, Eli Lilly, Talen Energy

U.S. RESEARCH ROUNDUP-Constellation Energy, Eli Lilly, Talen Energy Sept 13 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Constellation Energy, Eli Lilly and Talen Energy, on Friday. HIGHLIGHTS * Constellation Energy Corp CEG.O : Jefferies initiates with hold rating; target $183 * Eli Lilly LLY.N : JP Morgan raises target price to $1,100 from $1,050 * Moderna MRNA.O : JP Morgan cuts to underweight from neutral * Vo
A
C
C
F
F
H
H
H
I
K
W
F
D
T
Z
A
A
D
E
H
L

Buyout barons’ dirty secret shows hard times ahead

BREAKINGVIEWS-Buyout barons’ dirty secret shows hard times ahead The author is a Reuters Breakingviews columnist. The opinions expressed are his own. By Liam Proud LONDON, Sept 12 (Reuters Breakingviews) - Private-equity dealmakers like to boast about the ways they improve companies, like supercharging growth or trimming costs. The evidence, however, suggests that buyout barons owe a large chunk of their success to rising valuation multiples instead.
U
T

Agilent beats quarterly results on strong demand from biotech clients

Agilent beats quarterly results on strong demand from biotech clients Aug 21 (Reuters) - Agilent Technologies A.N on Wednesday beat Wall Street estimates for third-quarter profit and revenue, banking on strong demand for its medical tools and equipment used in clinical studies. "While market conditions continued to be challenged during the quarter, we saw steady signs of improvement as anticipated", said CEO Padraig McDonnell.
A
T

Bio-Techne meets Q4 profit estimates on demand for its diagnostics products

Bio-Techne meets Q4 profit estimates on demand for its diagnostics products Aug 7 (Reuters) - Bio-Techne TECH.O reported fourth-quarter profit in line with estimates on Wednesday as growth in the diagnostics and genomics unit offset weakness in its protein sciences unit. The Minnesota-based company posted an adjusted profit of 49 cents per share, meeting analysts' expectations according to LSEG data.
T

Leerink views Lilly and Sarepta as defensive stocks in turbulent market

BUZZ-Leerink views Lilly and Sarepta as defensive stocks in turbulent market ** Brokerages Leerink Partners says Eli Lilly LLY.N and Sarepta Therapeutics SRPT.O are among stocks it expects to outperform the broader market in "this turbulent period" of recession concerns ** Brokerage expects strong performance from the weight-loss and diabetes drug maker LLY on Wed, when it reports its earnings ** SRPT is a "a potential haven for investors seeking downside protection in a choppy market" due to po
A
B
M
T

Novartis, Viatris face new lawsuit over 'HeLa' cell misuse claims

UPDATE 1-Novartis, Viatris face new lawsuit over 'HeLa' cell misuse claims Adds response from Novartis in paragraph 3 By Blake Brittain Aug 5 (Reuters) - Novartis NOVN.S and Viatris VTRS.O were hit with a federal lawsuit in Maryland on Monday by the family of a woman whose tissue cells were taken from her body in the 1950s and used to fuel medical research and development.
N
T

Novartis, Viatris face new lawsuit over 'HeLa' cell misuse claims

Novartis, Viatris face new lawsuit over 'HeLa' cell misuse claims By Blake Brittain Aug 5 (Reuters) - Novartis NOVN.S and Viatris VTRS.O were hit with a federal lawsuit in Maryland on Monday by the family of a woman whose tissue cells were taken from her body in the 1950s and used to fuel medical research and development. The estate of Henrietta Lacks accused Novartis and Viatris of unlawfully profiting from the use of the "HeLa" cells to create drugs that have been "integral to their market pre
N
T

China's stuttering recovery darkens global corporate growth outlook

ANALYSIS-China's stuttering recovery darkens global corporate growth outlook By Medha Singh Aug 2 (Reuters) - Global burger chains to car manufacturers are increasingly feeling the pinch from a faltering recovery in the world's No. 2 economy , China, and are strapping in for a bumpy ride ahead. A protracted downturn in the property market and high levels of job insecurity have knocked the wind out of a fragile recovery in China, a global trading powerhouse, and the effects of its slowdown can be
A
B
B
B
H
K
L
L
M
P
Q
S
T
T

Bio-Rad Labs cuts annual revenue forecast on weak demand for diagnostics products

Bio-Rad Labs cuts annual revenue forecast on weak demand for diagnostics products Aug 1 (Reuters) - Bio-Rad Laboratories BIO.N cut its annual revenue growth forecast on Thursday, dragged down by weak demand for clinical diagnostics products from biotech clients. Shares of the diagnostics company fell 20% after the bell. Bio-Rad expects its full-year 2024 adjusted revenue to decline by about 2.5% to 4% on a currency-neutral basis, compared to its previous estimate of 1.0% to 2.5%.
T
W

Waters Corp cuts annual profit forecast on weak demand for lab equipment

Waters Corp cuts annual profit forecast on weak demand for lab equipment July 31 (Reuters) - Waters Corp WAT.N lowered its annual profit forecast as it anticipates reduced demand for its products and services used in drug development and research. Milford, Massachusetts-based Waters supplies lab equipment and technology for scientists across the world, with the majority of its revenue coming in from biopharma clients who use its tools for research and drug development.
T
W

Street View: Thermo's solid quarter signals easing demand weakness

BUZZ-Street View: Thermo's solid quarter signals easing demand weakness ** Thermo Fisher TMO.N raised its annual profit outlook on Wednesday and posted a better-than-expected profit in the second quarter, banking on improved demand for its tools and services used in clinical trials. SOLID QUARTER BY TMO SIGNALS RECOVERY ** RBC Capital Markets ("out
T

U.S. STOCKS Tesla, Lamb Weston, Blackstone Mortgage Trust

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Lamb Weston, Blackstone Mortgage Trust Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The Nasdaq plummeted to a one-month low on Wednesday after Tesla and Alphabet disappointed with lackluster earnings, prompting investors to question if the Big Tech and AI-fueled 2024 equity rally was sustainable in the long run.
A
C
F
G
M
S
S
T
V
C
T
U
U
E
T
L
O

U.S. STOCKS FTAI Aviation, Check Point, Sage Therapeutics

BUZZ-U.S. STOCKS ON THE MOVE-FTAI Aviation, Check Point, Sage Therapeutics Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street fell on Wednesday, with the tech-heavy Nasdaq leading declines after lackluster quarterly results from Tesla and Alphabet raised questions about the sustainability of the Big Tech and AI-led 2024 equity rally.
A
F
G
M
S
T
V
C
T
U
U
E
T
L
O

Thermo Fisher Scientific Inc reports results for the quarter ended in January - Earnings Summary

Thermo Fisher Scientific Inc reports results for the quarter ended in January - Earnings Summary Thermo Fisher Scientific Inc TMO.N reported quarterly adjusted earnings of $5.37​​ per share for the quarter ended in January, higher than the same quarter last year, when the company reported EPS of $5.15. The mean expectation of twenty two analysts for the quarter was for earnings of $5.12 per share.
T

Nasdaq futures set to slide at open after Tesla, Alphabet disappoint

US STOCKS-Nasdaq futures set to slide at open after Tesla, Alphabet disappoint For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window. Visa falls after missing revenue growth forecasts AT&T rises after beating subscriber-addition estimates Enphase Energy, Texas Instruments up after results Rivian falls; will face trial in Tesla trade secrets theft case Futures down: Dow 0.45%, S&P 500 0.90%, Nasdaq 1.39% Updated at 8:27 a.m.
A
A
G
M
N
T
V
T
U
U
U
T

Thermo Fisher drops as raised profit forecast fails to impress Wall Street

REFILE-BUZZ-Thermo Fisher drops as raised profit forecast fails to impress Wall Street Corrects typo in company name in the headline ** Shares of medical equipment maker Thermo Fisher TMO.N down 3% at $535 premarket ** Co raises annual profit forecast to between $21.29 and $22.07 per share vs previous forecast of $21.14 to $22.02 ** Analysts were e
T

Futures slide after Tesla, Alphabet earnings disappoint

US STOCKS-Futures slide after Tesla, Alphabet earnings disappoint For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window. AT&T rises after beating subscriber-addition estimates Enphase Energy, Texas Instruments up after results Visa falls after missing revenue growth forecasts Rivian falls; will face trial in Tesla trade secrets theft case Futures down: Dow 0.42%, S&P 500 0.69%, Nasdaq 1.04% Updated at 6:54 a.m.
A
A
G
M
N
T
V
T
U
U
U
T

Thermo Fisher lifts profit forecast as biotech demand shows signs of improvement

Thermo Fisher lifts profit forecast as biotech demand shows signs of improvement July 24 (Reuters) - Thermo Fisher TMO.N on Wednesday raised its annual profit outlook and posted a better-than-expected second-quarter profit, banking on improved demand for its tools and services used in clinical trials. Contract drug manufacturers witnessed cut back on spending by their biotech clients in 2023 amid rising interest rates.
T

High earnings bar, Harris polling bump

MORNING BID AMERICAS-High earnings bar, Harris polling bump A look at the day ahead in U.S. and global markets from Mike Dolan Wall St has suddenly become a tough crowd to please. Much like last week's cool market reception for decent earnings beats from streamer Netflix NFLX.O or chipmaker TSMC 2330.TW , Alphabet's GOOGL.O surprisingly muscular second quarter left its stock down 2% overnight - and even the artificial intelligence theme didn't wow the gallery.
A
B
E
G
G
L
N
N
T
T
U
G
J
U
U
U
F
S
T
A
A
U

Thermo Fisher Q2 Adjusted EPS USD 5.37 Vs. IBES Estimate USD 5.12

BRIEF-Thermo Fisher Q2 Adjusted EPS USD 5.37 Vs. IBES Estimate USD 5.12 Jul 24 (Reuters) - Thermo Fisher Q2 EPS USD 4.04. Q2 adjusted EBIT USD 2,347 million vs. IBES estimate USD 2,304 million Q2 adjusted net income USD 2,057 million vs. IBES estimate USD 1,963 million Q2 revenue USD 10,541 million vs. IBES estimate USD 10,511 million outlook FY re
T



조건

인기 자산

면책조항: XM Group 회사는 체결 전용 서비스와 온라인 거래 플랫폼에 대한 접근을 제공하여, 개인이 웹사이트에서 또는 웹사이트를 통해 이용 가능한 콘텐츠를 보거나 사용할 수 있도록 허용합니다. 이에 대해 변경하거나 확장할 의도는 없습니다. 이러한 접근 및 사용에는 다음 사항이 항상 적용됩니다: (i) 이용 약관, (ii) 위험 경고, (iii) 완전 면책조항. 따라서, 이러한 콘텐츠는 일반적인 정보에 불과합니다. 특히, 온라인 거래 플랫폼의 콘텐츠는 금융 시장에서의 거래에 대한 권유나 제안이 아닙니다. 금융 시장에서의 거래는 자본에 상당한 위험을 수반합니다.

온라인 거래 플랫폼에 공개된 모든 자료는 교육/정보 목적으로만 제공되며, 금융, 투자세 또는 거래 조언 및 권고, 거래 가격 기록, 금융 상품 또는 원치 않는 금융 프로모션의 거래 제안 또는 권유를 포함하지 않으며, 포함해서도 안됩니다.

이 웹사이트에 포함된 모든 의견, 뉴스, 리서치, 분석, 가격, 기타 정보 또는 제3자 사이트에 대한 링크와 같이 XM이 준비하는 콘텐츠 뿐만 아니라, 제3자 콘텐츠는 일반 시장 논평으로서 "현재" 기준으로 제공되며, 투자 조언으로 여겨지지 않습니다. 모든 콘텐츠가 투자 리서치로 해석되는 경우, 투자 리서치의 독립성을 촉진하기 위해 고안된 법적 요건에 따라 콘텐츠가 의도되지 않았으며, 준비되지 않았다는 점을 인지하고 동의해야 합니다. 따라서, 관련 법률 및 규정에 따른 마케팅 커뮤니케이션이라고 간주됩니다. 여기에서 접근할 수 있는 앞서 언급한 정보에 대한 비독립 투자 리서치 및 위험 경고 알림을 읽고, 이해하시기 바랍니다.

리스크 경고: 고객님의 자본이 위험에 노출 될 수 있습니다. 레버리지 상품은 모든 분들에게 적합하지 않을수 있습니다. 당사의 리스크 공시를 참고하시기 바랍니다.